Lakeshore Biopharma Co. Ltd.Preferred / convertible

13F holders, Q4 2025 (December 31)
3holders
0new positions
0sold out
$0.00avg. 13F price*

At the end of Q4 2025, 3 institutions reported holding Lakeshore Biopharma Co. Ltd. in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were HGC Investment Management Inc. ($35), Ancora Advisors LLC ($15) and SkyView Investment Advisors, LLC ($0).

Company
Lakeshore Biopharma Co. Ltd.
Filed as
SUMMIT HEALTHCARE ACQUISITION (Q4 2025)
CUSIP
G9845F117
Latest filing quarter
Q2 2026

History

Number of 13F holders

0510152025 Q1 2024: 25Q1 2024Q2 2024: 23Q2 2024Q3 2024: 21Q3 2024Q4 2024: 18Q4 2024Q1 2025: 18Q1 2025Q2 2025: 19Q2 2025Q3 2025: 3Q3 2025Q4 2025: 3Q4 2025Q1 2026: 2Q1 2026Q2 2026: 2Q2 2026

Total Exit/New Position Q3 2025 → Q4 2025

InstitutionsTotal Value
New Positions0$0
Exits0$0

Ownership 3 holders

HGC Investment Management Inc. — No change 5,000 $35
Ancora Advisors LLC — No change 5,050 $15
SkyView Investment Advisors, LLC — No change 12,210 $0

"% of holder's portfolio" is LAKESHORE BIOPHARMA CO LTD's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.